Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels
- Conditions
- Interventions
- First Posted Date
- 2020-08-03
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 56
- Registration Number
- NCT04495608
- Locations
- 🇫🇷
Service de Néphrologie Rhumatologie Dermatologie Pédiatrique, Bron, France
🇫🇷CHU de Nantes, Nantes, France
🇫🇷Hôpital Universitaire Necker-Enfants Malades, Paris, France
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT04464577
- Locations
- 🇺🇸
Local Institution, Salt Lake City, Utah, United States
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Mundipharma Research Limited
- Target Recruit Count
- 600
- Registration Number
- NCT04368559
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇧🇪University Hospitals Leuven, Campus Gasthuisberg - UZ Leuven, Leuven, Belgium
🇫🇷Grenoble Alpes University Hospital Center, Grenoble, France
Generation of Biological Samples Positive to Fluconazole for Anti-Doping Control
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Parc de Salut Mar
- Target Recruit Count
- 2
- Registration Number
- NCT04201054
- Locations
- 🇪🇸
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04193319
- Locations
- 🇨🇳
Early Cancer Research Center of Hunan Cancer Hospital, Hunan, Hunan, China
Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2021-07-21
- Target Recruit Count
- 104
- Registration Number
- NCT04132115
- Locations
- 🇮🇹
Anesthesiology and Intensive Care Clinic - Department of Medicine - ASUIUD, Udine, Italy
🇮🇹Terapia Intensiva 1, Udine, Italy
Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting Conditions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Pharmtechnology LLC
- Target Recruit Count
- 26
- Registration Number
- NCT04038008
- Locations
- 🇨🇦
Altasciences Company Inc., Mont-Royal, Quebec, Canada
Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 356
- Registration Number
- NCT03945448
- Locations
- 🇺🇬
infectious Disease Institute Kampala,Uganda, Kampala, Uganda
PTX3-targeted Antifungal Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Bochud Pierre-Yves
- Target Recruit Count
- 320
- Registration Number
- NCT03828773
- Locations
- 🇫🇷
Henri Mondor Hospital, Créteil, Ile De France, France
🇧🇪University Hospital Leuven (UZ Leuven), Leuven, Belgium
🇧🇪AZ Sint-Jan Hospital, Bruges, Belgium
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Cidara Therapeutics Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT03667690
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Tel Hashomer, Israel
🇪🇸Hospital Clinic of Barcelona, Barcelona, Spain
🇮🇹University Polyclinic Foundation Agostino Gemelli - IRCCS, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.